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Seventy two subjects with OCD were compared with 18 normal healthy volunteers on multiple 
neuroendocrine responses to clonidine. Significant heterogeneity in OCD was observed in responses 
of growth hormone. There was also significant disturbances in Cortisol and ACTH release. An 
interactional model for noradrenergic and serotonergic dysfunction in OCD is discussed. 
Obsessive Compulsive Disorder 
(OCD), although initially tought to be a rela-
tively uncommon disease, is now recognised to 
occur in about 3% of the general population 
(Myers et al., 1984). It is not surprising therefore 
that there is increasing interest in the biological 
basis of this disorder (Zohar et al., 1987,1988). 
Most of this interest has focused on the 
neurochemistry of the disorder. The most con-
vincing evidence which currently exists impli-
cates the serotonergic system in the form of [1] 
abnormalities of ^I-imipramine binding, [2] 
reduction CSF 5-hydroxy indole acetic acid 
levels, [3] exacerbation of symptoms with a 
serotonergic agonist - m-chlorophenyl-
piperazine, with a blunting of neuroendocrine 
responses; a change which normalises after 
treatment with clomipramine/ fluvoxamine and 
[4] response to serotonin uptake inhibitors and 
precursors (Khanna, 1988; 1992 and Zohar and 
Insel, 1987). However it is widely accepted that 
the serotonergic model does not explain all ab-
normalities in OCD as treatment non-
responders are recognised. The most extreme 
position is probably adopted by Marks (1987) 
who believes that the effect of serotonin uptake 
inhibitors is only in the associated depression 
and has no effect on the obsessive compulsive 
state per se. 
There is, in addition, some evidence to 
suggest that there may be a noradrenergic dys-
function in OCD, as in depression. A blunted 
growth hormone response to clonidine in OCD 
has been reported (Siever et al~, 1983). While 
Hollander et al. (1988) reported subjective im-
provement after intravenous administration of 
clonidine, they subsequently did not cor-
roborate this with the hormonal correlate (Hol-
lander, 1988). In addition there exist reports of 
the clinical efficacy of clonidine in single cases 
(Knesevich, 1982; Hollander et of., 1988; Up-
sedge and Prothero, 1987) and openirials (Rao 
and Rao, 1988; Khanna 1990). Clonodine is also 
found efffective in treatment of GiOes de la 
Tourette syndrome, a disorder thought to be 
allied in many respects with OCD (Khanna et 
al, 1987). Leeetal. (1990) found an increased 
number of alpha-2 receptor binding sites to 
Hi -clonidine in platelets in OCD. There thus 
exists a strong body of evidence to suggest that 
there may be noradrenergic dysfunction in 
OCD, which however has not been adequately 
explored so far. 
One of the strategies commonly used in 
studying noradrenergic function in depression 
is the neuroendocrine response to clonidine 
(Siever and Uhde, 1984). The measure moat 
commonly used in the growth hormone 
response. However it is now recognised that 
there is alpha-2 adrenergic involvement in the 
control of several other hormones, specifically 
Cortisol, ACTH and perhaps prolactin (Bennett, 
and Whitehead, 1983) and consistent changes 
in these parameters have been reported in nor-
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mals (Khanna et al., 1990). There have been 
recent reports of the usage of such strategies as 
marker of the noradrenergic dysfunctional state-
in melancholic depression (Amsterdam et al., 
1989). The usage of multiple neuroendocrine 
marker in response to alpha-2 agonists like 
clonidine helps assessing both pre and post-
synaptic noradrenergic functions. 
The current study is an attempt at ex-
ploring noradrenergic function in OCD using 
multiple neuroendocrine responses to 
clonidine and determining whether there are 
different subgroups based on noradrenergic 
function in OCD. 
METHODOLOGY 
PATIENTS 
The patients included in this study met 
DSM III criteria for OCD (American 
Psychiatric Association, 1980). Patients charac-
teristics are given in Table 2. Subjects who had 
Hamilton Depression Scores (Hamilton, 1960) 
greater than 11 were excluded from the study. 
All subjects gave written consent to participate 
in this study: None of the patients had any major 
co-existent physical disorder such as hyperten-
sion. Patients with history suggestive of other 
co- morbid psychiatric disorders, such as Panic 
Disorder, or Alcohol abuse and dependence 
were also excluded from this study. Subjects 
were rated onLeyton's Obsessional Inventory 
(Copper, 1970) and the scores are given in 
Table 2. Subjects who had only obsessions and 
those with obsessions and compulsions were 
regarded as two separate groups. The duration 
of illness ranged from 0.6 to 14 years. All 
patients were drug free for a minimum period 
of 4 weeks prior to the conduct of this study. 
None of the patients had a past history of tic 
disorder or major depression which was not 
secondary to OCD or had psychotic or en-
dogenous features. There were no clinically sig-
nificant laboratory findings. All subjects were 
within 20% of their ideal weight. None of the 
subjects had a past clinical history of hepatic, 
renal, endocrinological or cardiovascular ill-
ness. None of the female subjects were oh oral 
contraceptives, but the study was conducted 
irrespective of the period of their menstrual 
cycle. There were a total of 72 subjects with 
OCD who participated in this study. 
HEALTHY VOLUNTEERS 
Eighteen drug-free healthy controls 
formed the normal sample for this study. They 
were recruited from the employees of the in-
stitute. Sociodemographic details are given in 
Table 1. All of the subjects were studied under 
similar experimental conditions. None of the 
subject had any coexistent or past history of 
psychiatric illness. All were free of major physi-
cal illness at the time of conducting this inves-
tigation and none had a past history of 
endocrines, hepatic, renal or cardiovascular 
disorder. Further there was no historical 
evidence of psychiatric morbidity in their first 
degree relatives. 
Table 1: Sample charateristics 
Population 
Normal 
OCD-
Total 
OCD-
Obsessions 
OCD 
Compul 
sions 
"N 
18 
72 
21 
51 
Age 
19-43 
(25.4 
S J>. 52) 
17-51 
(24.6 
SJX7.8) 
17-42 
(21.8 
S.D.5.2) 
19-51 
(23.8 
SJX9.1) 
Male: 
Female 
11:7 
41:31 
14:7 
24:24 
LOI 
Score 
46-59 
(53.1 
SJD.6.2) 
46-53 
(54.1 
S.D.4.2) 
47-59 
(517 
S.D.7J) 266  SUMANT KHANNA et al. 
PROCEDURE 
All tests were conducted between 9 and 
10 a.m. after an overnight fast. Clonidine 
hydrochloride, in a dose of 2 microgram/Kg 
body weight was diluted in 10 cc of normal 
saline and slowly infused, through a heparin 
locked i.v. catheter. Clotted blood for hormone 
assay was collected at 0,15,30 and 60 minutes. 
Some subject experienced transient drowsiness 
during the study, but no other side effect was 
reported. 
Details of hormone kit characteristics, 
with regard to intra and inter-assay coefficient 
of variation and the sensitivity are given in table 
2. Growth hormone (GH) concentration were 
determined by means of a double antibody 
radio- immuno assay technique by kits obtained 
from Bhabha Atomic Research Centre, Bom-
bay. Cortisol concentrations were determined 
by a single antibody radio-immunoassay techni-
que using kits obtained from Leeco Diagnos-
tics, Michigan, USA. Prolactin concentrations 
were determined by a double antibody radio-
immunoassay technique with kits obtained from 
Leeco Diagnostics, Michigan, USA. ACTH 
concentrations were also determined by a 
double antibody radio-immuno assay technique 
using kits obtained from Diagnostics Products 
Corporation, Los Angeles, USA. All assays in-
volving samples from the same subjects were 
simultaneously performed in duplicate. 
Table 2 : Hormone kit characteristics 
Hormone 
GH 
Cortisol 
Prolactin 
ACTH 
Coefficient of variation 
Intra-assay 
6.4 
6.29 
4.2 
2.7 
Inter-assay 
6.2 
632 
2.5 
2.2 
Sensitivity 
0.3 ng/ml 
0.21micro 
G/dl 
0.9 ng/ml 
14 pg/ml 
AH assays done by radio immuno assay 
STATISTICAL PROCEDURES 
Growth hormone, Cortisol, ACTH and 
prolactin levels are compared [1] between nor-
mal and the whole OCD sample and [2] between 
pure obsessionals and compulsives. The 
parameters taken for initial analysis were [1] 
baseline values, [2] maximal value and [3] max-
imal change from baseline [Delta-Max]. The 
comparison was done using t test. 
We also performed Analysis of Variance 
(ANOVA) between [1] normals and the total 
OCD sample and [2] pure obsessionals and 
compulsives. ANOVA was performed for 
group, time and group x time (two way 
ANOVA). 
Correlation was also done for baseline 
and delta-max hormonal values and Leyton's 
Obsessional Inventry scores. 
RESULTS 
There was significant blunting of the 
growth hormone response to clonidine when 
the whole OCD group was considered (Table 3, 
Figure 1), but there was no statistically sig-
nificant baseline difference. Subsequently sub-
jects were divided into those whose growth 
hormone response was more than 10 ng/mt 
(Augmenters) and less than 5 ng/ml (Blunted 
response).The intermediate group was 
regarded as having .response similar to controls 
(no response) as shown in Table 4. There was a 
significant excess of blunted response in pure 
obsessional and augmented response in com-
pulsive subjects. 
There was no significant differences in 
the prolactin response between normal and 
OCD subjects (Table 5, Fig. 2). The Cortisol 
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groups as compared to normals (Table 6, Fig. 
3). The ACTH response was significantly 
lowerd for the pure obsessional group although 
this trend was observed for all OCD subjects 
(Table 7, Fig. 4). There was no significant cor-
* relation between scores in Leyton's Obsessional 
Inventory and baseline and delta-max hormone 
values. 
On ANOVA, there was significant 
group differences betweeen OCD and normals 
for growth hormone, Cortisol and ACTH. Time 
differences were significant only for growth 
hormone and ACTH. Two way ANOVA 
showed that there were significant differences 
for growth hormone, Cortisol and ACTH (Table 
8). 
When pure obsessionals were compared 
with compulsives (Table 9) groups, time and 
interactional differences were observed mainly 
for ACTH. 
Table 3: Growth hormone responses to 
clonidine (ng/ml) 
Group 
Normal 
OCD-
Total 
OCD-
Compul 
sions 
OCD-
Obsess 
ions 
Baseline 
1.84 
(1.16) 
2.11 
(132) 
2.18 
(1.16) 
2.09 
(L54) 
Peak 
1232 
(4.18) 
931 
(3.44) 
9.44 
(333) 
9.11 
(4.02) 
Delta-max 
10.48 
(5.41) 
7.20 
(3.36) 
7.26 
(3.91) 
7.02 
(4.11) 
Normal comparisons with other groups 
p<0.05 
Table 4: Patterns of Growth hormone 
response to clonidine 
OCD-group 
Augmenters 
No Response 
Blunted 
Peak  Delta-
Max 
12.4 103 
9.4 7.2 
5J9 3.9 
Obsessions: 
Compulsions 
4:26 
1:12 
16:14 
Table 5: Prolactin responses to Clonidine 
(ng/ml) 
Group 
Controls 
OCD-Total 
OCD Ob 
sessions 
OCD 
Compulsions 
Baseline 
7.14 
(4.22) 
6.62 
(5.11) 
6.74 
(4.96) 
6.57 
(5.22) 
Peak 
13.46 
(631) 
12.11 
(5.29) 
13.01 
(632) 
11.74 
(5.11) 
Delta-
max 
632 
(5.28) 
5.49 
(4.88) 
6.27 
(4.93) 
5.17 
(5.16) 
All comparosons are non-significant 
Table 6: Cortisol response to clonidine 
(micro G/dl) 
Group 
Controls 
OCD-Total 
OCD 
Obsessions 
OCD 
Compulsions 
Baseline 
13.14 
(632) 
11.93 
(7.14) 
12.11 
(6.99) 
11.86 
(7.24) 
Peak 
732 
(3.44) 
5.44 
(4.92) 
531 
(4.78) 
5.49 
(4.74) 
Delta-
Max 
5.82 
(5.21) 
6.49 
(4.78) 
6.80 
(432) 
637 
(4.44) 
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Table 7: ACTH response to clonidine (pg/ml) 
Group 
Controls 
OCD-total 
OCD-
Obsessions 
OCD-
Compulsions 
Baseline 
24.32 
(15.14) 
25.15 
(16.16) 
25.68 
(15.92) 
24.93 
(16.01) 
Peak 
17.44 
(11.32) 
16.69 
(12.22) 
1557 
(7.44) 
17.02 
(10.07) 
Delta-Max 
6.88 
(9.16) 
8.46 
(7.11) 
9.81 
(6.17) 
7.90 
(7.12) 
Table 8: ANOVA for endocrine measures 
(Normals versus OCD) 
Term 
Growth hormone 
Group 
Time 
Group x Time 
Cortisol 
Group 
Time 
Group x Time 
Prolactin 
Group 
Time 
Group x Time 
ACTH 
Group 
Time 
Group x Time 
F 
21.9789 
113246 
10.4944 
9.06709 
2.24247 
2.93758 
0.56755 
2.15566 
0.51858 
6.07161 
3.22398 
1.3186 
d.f. 
1,88 
3,356 
3356 
1,88 
3356 
3,356 
1,88 
3,356 
3,356 
1,88 
3,356 
3,356 
P 
< 0.0001 
< 0.0001 
< 0.0001 
< 0.0034 
< 0.0832 
< 0.336 
< 0.4531 
< 0.3968 
< 0.6724 
< 0.0157 
< 0.0231 
< 0.0001 
Table 9: ANOVA for endocrine measures 
(Pure Obsessionals versus Compulsives) 
Term 
Growth 
hormone 
Group 
Time 
Group x Time 
Cortisol 
Group 
Time 
Group x Time 
Prolactin 
Group 
Time 
F 
3.19191 
11.40388 
2.18370 
3.99032 
3.07043 
2.02101 
1.02761 
2.44934 
Group x Time 0.723661 
ACTH 
Group 
Time 
Group x Time 
6.35536 
9.73842 
5.20598 
d.f. 
1,70 
3,212 
3,212 
1,70 
3,212 
3,212 
1,70 
3,212 
3,212 
1,70 
3,212 
3,212 
P 
0.0784 
< 0.0001 
0.0911 
0.0497 
0.0291 
0.1121 
0.3142 
0.0648 
0J5441 
0.0134 
< 0.0001 
0.0018 
DISCUSSION 
As has been discussed in the introduc-
tion, there is very strong evidence which impli-
cates serotonergic dysfunction in OCD. 
Although it was initially thought that it is the 
5HTIB receptor which undergoes behavioural 
upregalation (Zohar et al., 1987) this was later 
believed to be the 5HTic receptor since the 
former was not identified in the human brain 
(Kahn and Wetzler, 1991). There however con-
tinues to be controversy regarding the exact 
receptor mechanism of action of mCPP in the 
human brain (Kahn and Wetzler, 1991), and the 
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QROUTH HORHONC RESPONSE TO CLONIDINE 
- NORMALS 
+ OCD 
PROLACTIN  TO CLONXDXNK 
* OCD 
;-* 
\ 
TIME (minutra)  TINE <minut*«> 
CORTISOL RESPONSE TO CLONIDINE 
- NORMAL* 
+ OCO 
TIME (minutmm) 270  SUMANT KHANNA et al. 
ACTH RESPONSE TO CLONIOXNE 
NORMALS 
OCO 
« 
S m 
M M 
Tim CainutM) 
H0RA9RENER6IC-SEROT(»EReiC HODS. FOR 
OBSESSIVE COMPULSIVE DISORDER 
(3SESSI0K5 I CCmJLSIOHS 
my OKESSIONS 
(JM ADRENERGIC HVPERSEHSITIVITY 
ADRENER6IC SUBSEHSITIVITY 
KHAVIORAL SEROTONERGIC HYPERSENSITIVITY 
receptor subtypes are likely to be involved in the 
neurobiology of OCD (Murphy et al., 1990). 
Neverthless the current study docu-
ments noradrenergic dysfunction in OCD. 
When taken as a whole it appears that there is 
noradrenergic down-regulation in OCD, as ini-
tially reported (Siever et al., 1983). Nevetheless 
when the OCD group is subdivided with a rela-
tively large frame it becomes obvious that such 
a generalisation is sweeping and that there ex-
ists noradrenergic heterogeniety in OCD. This 
explains the observation of a normal to aug-
mented growth hormone response to OCD ob-
served by Hollander (1989). What is perhaps 
most interesting is the observation that pure 
obsessionals tend to have a more down regu-
lated noradrenergic system as compared to the 
compulsives. 
When Zohar et al. (1987, 1988) ad-
ministered m-chlorophenylpiperazine to OCD 
subjects they used to try and stimulate the en-
vironment in which such obsessions occur. 
However it is well recognised that such a situa-
tion could be stressful and lead to noradrener-
gic stimunlation. When Khanna et al. (1989) 
repeated this study without invoking such 
stressful environments they were not able to 
observe exacerbations in obsessive-compulsive 
psychopathology. Even when this agent is given 
intravenously the same observation is made MULTIPLE ENDOCRINE RESPONSES TO CLONIDINE IN OCD 271 
(Charney et al., 1988). It therefore seems 
reasonable to presume that a 5HT hypersensi-
tive state is a precondition for the development 
of the OCD, but it on its own may not be suffi-
cient. What is perhaps required in addition 
either a state wherein exogenously produced 
stress causes noradrenergic release, or there 
needs to be an endogenous noradrenergic state 
which produces such psychopathology (Fig. S). 
The interesting differentiation between 
obsessionals and compulsives assume great 
therapeutic importance, as behavioural lines of 
management are far more successful for com-
pulsive (Marks, 1987) than for pure obses-
sionals. Perhaps these later subjects require 
correction of their noradrenergic state to 
facilitate clinical recovery. 
At a methodological plane, it appears 
from this investigation that the ACTH response 
to clonidine is a fairly sensitive marker of 
noradrenergic function. However it is obvious 
that a study on OCD, in which noradrenergic 
dysfunction is only now being proposed, would 
not be sufficient to support this. Nevertheless 
the rapid rise in ACTH after clonidine ad-
ministration makes it an important marker for 
such an approach. 
This study aims to integrate the 
serotonergic biology of OCD with noradrener-
gic dysfunction which can be produced by a host 
of conditions, such as stress. It may well help in 
linking behavioural and biiological approaches 
to the undertaking of OCD and its subsequent 
therapy. However it would be perhaps too early 
and too simplistic to accept this model as being 
final. It needs replication and a greater under-
standing of the differentiation of pure obses-
sionals and compulsives. It does not rule out the 
possibility of involvement of other 
neurotransmitters and behavioural models, but 
aims at opening the horizon regarding the un-
dertaking of the very personally distressful ob-
sessive compulsive state. 
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